Shares of OpGen, Inc. (NASDAQ:OPGN – Get Rating) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.50 and traded as low as $0.41. OpGen shares last traded at $0.42, with a volume of 120,439 shares.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on OPGN. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OpGen in a report on Friday, June 10th. Alliance Global Partners downgraded OpGen to a “neutral” rating in a report on Tuesday, July 19th. Finally, StockNews.com started coverage on OpGen in a report on Thursday. They issued a “sell” rating for the company.
OpGen Trading Down 6.8 %
The stock has a market capitalization of $18.71 million, a price-to-earnings ratio of -0.48 and a beta of -0.37. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.32 and a current ratio of 1.40. The firm has a fifty day moving average of $0.50 and a 200-day moving average of $0.57.
Hedge Funds Weigh In On OpGen
A hedge fund recently bought a new stake in OpGen stock. GSA Capital Partners LLP acquired a new stake in OpGen, Inc. (NASDAQ:OPGN – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 97,810 shares of the medical research company’s stock, valued at approximately $73,000. GSA Capital Partners LLP owned about 0.21% of OpGen at the end of the most recent reporting period. 7.24% of the stock is owned by hedge funds and other institutional investors.
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
- Get a free copy of the StockNews.com research report on OpGen (OPGN)
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.